CSL has used the first session of its capital markets fiesta in Chicago to assure investors the company has a flu vaccine ...

Amid a slew of secondary equity raisings and at least two planned IPOs, the biotech sector is ending a difficult year on a ...

October was rough for Aussie tech, with Xero and WiseTech dragging the XIJ down 8pc, but behind the red ink a new crop of ...

The ASX 200 Health Care Index fell 4.83% in October and is now deep in red territory for 2025 as heavy CSL fall weighs on ...

Older Australians who stop working but fail to inform their super funds of their retirement are paying 15 per cent tax on their super.

Tryptamine Therapeutics (ASX:TYP) raises $6.1 million to advance its clinical trial for TRP-8803 for treating binge eating ...

The ASX drifted lower by lunchtime as miners and tech fell again. Meanwhile, Michael Burry has resurfaced, with fresh shorts ...

Race Oncology, EZZ Life Science and Neurotech International are among ASX health companies reporting quarterly results.

The ASX biotech sector ran strongly in October, but the big-cap thoroughbreds found the track conditions more challenging.

The executive team behind De Grey Mining has resurfaced, powering gains at the Richardson Street Group's Bellavista Resources ...

REA Group’s Eleanor Creagh reckons Bullock will hold fire at 3.6% today, calling last week’s CPI strong print a “watchful ...

Lithium may have turned a corner in October, while gold and copper both touched record highs before late pullbacks.